Idorsia Ltd at JPMorgan Healthcare Conference Transcript
Good afternoon. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the Idorsia presentation. So you're going to hear from Idorsia CEO, Jean-Paul Clozel, and we have about a 20-minute presentation, and then we'll have 15, 20 minutes for your questions, which we're going to take in the same room. So with that said, thanks very much for joining us today, Jean-Paul, looking forward to the presentation.
Thank you. You just have swallowed 30 seconds from the presentation. Okay. So good afternoon, everybody. I think Idorsia -- for Idorsia, the year 2023 is going to be really very interesting. And this is really because of all the work, and after this disclaimer, because of all the work that we did in 2022. And in this 2022 year, we achieved a lot.
We achieved a lot because we became a commercial company. Idorsia launched QUVIVIQ,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |